Exome sequencing: New insights into lipoprotein disorders

Current Cardiology Reports

Volumn 16, Issue 7, 2014, Pages

  Farhan, Sali M K ^a   Hegele, Robert A ^a,b  

^a WESTERN UNIVERSITY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Diagnosis, Mutation; Dyslipidemia; Exome sequencing; Hypercholesterolemia; Hypertriglyceridemia; Inherited disorders; Lipoprotein disorders; Next generation DNA sequencing

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G5; APOLIPOPROTEIN B; APOLIPOPROTEIN E; LIPOPROTEIN LIPASE;

ABCA1 GENE; ABCG5 GENE; ANGPTL3 GENE; APOB GENE; APOE GENE; DISEASE SEVERITY; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DYSLIPIDEMIA; EXOME; FAMILIAL HYPOALPHALIPOPROTEINEMIA; GENE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HETEROZYGOSITY; HIGH THROUGHPUT SCREENING; HUMAN; HYPERCHOLESTEROLEMIA; HYPOLIPEMIA; LIPA GENE; LPL GENE; MEDICAL RESEARCH; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; DNA SEQUENCE; GENETIC PREDISPOSITION; GENETICS; MUTATION; PROCEDURES;

DYSLIPIDEMIAS; EXOME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; SEQUENCE ANALYSIS, DNA;

EID: 84901734759     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-014-0507-2     Document Type: Review

References (44)

1. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921. (Pubitemid 32165345)
2. Ng SB, Nickerson DA, Bamshad MJ, et al. Massively parallel sequencing and rare disease. Hum Mol Genet. 2010;19:R119-24.
3. • Boycott KM, Vanstone MR, Bulman DE, et al. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet. 2013;14:681-91. An excellent overview of the impact of next-generation sequencing as applied to rare single disorders across a wide range of medicial specialities and affected organ systems.
4. Do R, Kathiresan S, Abecasis GR. Exome sequencing and complex disease: practical aspects of rare variant association studies. Hum Mol Genet. 2012;21:R1- 9.
5. Stranger BE, Stahl EA, Raj T. Progress and promise of genomewide association studies for human complex trait genetics. Genetics. 2011;187:367-83.
6. Jiang YH, Yuen RK, Jin X, et al. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am J Hum Genet. 2013;93:249-63.
7. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in app protects against alzheimer's disease and age-related cognitive decline. Nature. 2012;488:96-9.
8. Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of gwas loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet. 2011;43:1066-73.
9. Wheeler DA, Wang L. From human genome to cancer genome: the first decade. Genome Res. 2013;23:1054-62.
10. Harismendy O, Ng PC, Strausberg RL, et al. Evaluation of next generation sequencing platforms for population targeted sequencing studies. Genome Biol. 2009;10:R32.
11. Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 2010;11:31-46.
12. Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. Clin Chem. 2009;55:641-58.
13. Voelkerding KV, Dames S, Durtschi JD. Next generation sequencing for clinical diagnostics-principles and application to targeted resequencing for hypertrophic cardiomyopathy: a paper from the 2009 william beaumont hospital symposium on molecular pathology. J Mol Diagn. 2010;12:539-51.
14. Majewski J, Schwartzentruber J, Lalonde E, et al. What can exome sequencing do for you? J Med Genet. 2011;48:580-9.
15. Lemke JR, Riesch E, Scheurenbrand T, et al. Targeted next generation sequencing as a diagnostic tool in epileptic disorders. Epilepsia. 2012;53:1387-98.
16. Kaur H, Mao S, Shah S, et al. Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ. Expert Rev Mol Diagn. 2013;13:151-65.
17. Wang F, Wang H, Tuan HF, et al. Next generation sequencing-based molecular diagnosis of retinitis pigmentosa: Identification of a novel genotype-phenotype correlation and clinical refinements. Hum Genet. 2013
18. • Rios J, Stein E, Shendure J, et al. Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia. Hum Mol Genet. 2010;19:4313-8. First instance of whole genome sequencing applied to diagnose a patient with severe dyslipidemia.
19. Fu J, Kwok S, Sinai L, et al. Western database of lipid variants (wdlv): a catalogue of genetic variants in monogenic dyslipidemias. Can J Cardiol. 2013;29:934-9.
20. Lee MH, Lu K, Hazard S, et al. Identification of a gene, abcg5, important in the regulation of dietary cholesterol absorption. Nat Genet. 2001;27:79-83. (Pubitemid 32044523)
21. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent abc transporters. Science. 2000;290:1771-5. (Pubitemid 32004809)
22. Salen G, Patel S, Batta AK. Sitosterolemia. Cardiovasc Drug Rev. 2002;20:255-70. (Pubitemid 36105780)
23. Wang J, Joy T, Mymin D, et al. Phenotypic heterogeneity of sitosterolemia. J Lipid Res. 2004;45:2361-7. (Pubitemid 39602984)
24. Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, angptl3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363:2220-7.
25. Pulai JI, Neuman RJ, Groenewegen AW, et al. Genetic heterogeneity in familial hypobetalipoproteinemia: linkage and non-linkage to the apob gene in caucasian families. Am J Med Genet. 1998;76:79-86. (Pubitemid 28104307)
26. Koishi R, Ando Y, Ono M, et al. Angptl3 regulates lipid metabolism in mice. Nat Genet. 2002;30:151-7.
27. Shimizugawa T, Ono M, Shimamura M, et al. Angptl3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem. 2002;277:33742-8.
28. Shimamura M, Matsuda M, Yasumo H, et al. Angiopoietin-like protein3 regulates plasma hdl cholesterol through suppression of endothelial lipase. Arterioscler Thromb Vasc Biol. 2007;27:366-72. (Pubitemid 46143053)
29. Romeo S, Yin W, Kozlitina J, et al. Rare loss-of-function mutations in angptl family members contribute to plasma triglyceride levels in humans. J Clin Invest. 2009;119:70-9.
30. Minicocci I, Santini S, Cantisani V, et al. Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. J Lipid Res. 2013;54:3481-90.
31. Reddy MV, Iatan I, Weissglas-Volkov D, et al. Exome sequencing identifies 2 rare variants for low high-density lipoprotein cholesterol in an extended family. Circ Cardiovasc Genet. 2012;5:538-46.
32. • Marduel M, Ouguerram K, Serre V, et al. Description of a large family with autosomal dominant hypercholesterolemia associated with the apoe p.Leu167del mutation. Hum Mutat. 2013;34:83-7. This paper identified the same APOE gene mutation in independent families with autosomal dominant hypercholesterolemia.
33. • Awan Z, Choi HY, Stitziel N, et al. Apoe p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis. 2013;231:218-22. This paper identified the same APOE gene mutation in independent families with autosomal dominant hypercholesterolemia.
34. Rahalkar AR, Wang J, Sirrs S, et al. An unusual case of severe hypertriglyceridemia and splenomegaly. Clin Chem. 2008;54:606-10. discussion 610-11.
35. Solanas-Barca M, de Castro-Oros I, Mateo-Gallego R, et al. Apolipoprotein e gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia. Atherosclerosis. 2012;222:449-55.
36. Faivre L, Saugier-Veber P, Pais de Barros JP, et al. Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein e p.Leu149delmutation. Eur J Hum Genet. 2005;13:1186-91.
37. • Cefalu AB, Pirruccello JP, Noto D, et al. A novel apob mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. Arterioscler Thromb Vasc Biol. 2013;33:2021-5. Whole-exome sequencing was used to identify a mutation in APOB, indicating that this family had a phenotypic variant of hypobetalipoproteinemia.
38. Lee J, Hegele RA. Abetalipoproteinemia and homozygous hypobetalipoproteinemia: A framework for diagnosis and management. J Inherit Metab Dis. 2013
39. • Stitziel NO, Fouchier SW, Sjouke B, et al. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2013;33:2909-14. Whole exome sequencing was used to identify a mutation in LIPA, indicating that this family with hypercholesterolemia had a phenotypic variant of cholesterol ester storage disease.
40. • Johansen CT, Dube JB, Loyzer MN, et al. Lipidseq: a next-generation clinical resequencing panel for monogenic dyslipidemias. J Lipid Res. 2014. doi:10.1194/jlr.D045963. An example of a high-throughput method that can be used to diagnose patients with monogenic dyslipidemia encountered clinically.
41. Collins FS, Hamburg MA. First fda authorization for nextgeneration sequencer. N Engl J Med. 2013;369:2369-71.
42. Pollex RL, Hegele RA. Genetic determinants of the metabolic syndrome. Nat Clin Pract Cardiovasc Med. 2006;3:482-9. (Pubitemid 44288461)
43. Hegele RA, Joy TR, Al-Attar SA, et al. Thematic review series: adipocyte biology. Lipodystrophies: windows on adipose biology and metabolism. J Lipid Res. 2007;48:1433-44. (Pubitemid 47312005)
44. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707-13.